OSE Immunotherapeutics and CHU de Nantes presented a positive analysis of data from the first use of anti-CD28 FR104/VEL-101 in kidney transplantation, in an oral session at the annual ATC congress in Philadelphia (June 1-5).

The data show the safety of the product used in combination, and the first signs of efficacy without an episode of acute rejection after one year of post-renal transplant follow-up in all patients in the study", explains Gilles Blancho, the study's principal investigator.

The results of our exploration of the safety profile of FR104/VEL-101 seem promising and encouraging for the continuation of phase 2 development in kidney transplant patients awaiting innovative solutions", he continues.

Copyright (c) 2024 CercleFinance.com. All rights reserved.